Terence W. Friedlander

Terence W. Friedlander, MD, is a Professor in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine. He specializes in genitourinary medical oncology, with a clinical and research focus on bladder, prostate, and kidney cancers. Dr. Friedlander also serves as Chief of the ZSFG Division of Hematology and Oncology, where he leads a large clinical research program dedicated to developing novel therapeutics and improving patient access to care.

• Medical Degree: NYU Grossman School of Medicine, 2003
• Residency: Internal Medicine, UCSF, 2004
• Fellowship: Hematology-Oncology, UCSF, 2010
• Fellowship: Urologic Oncology, UCSF, 2011
• MA in Medical Ethics, Utrecht University, 2007

Dr. Friedlander’s research is centered on understanding the biology of urologic malignancies and developing innovative treatments, particularly in the areas of immunotherapy, genomics, and circulating tumor cells. His work aims to overcome treatment resistance and improve outcomes for patients with advanced prostate and bladder cancers. He employs a translational approach, bridging laboratory findings with clinical applications through numerous clinical trials.

His recent publications highlight a strong emphasis on combination immunotherapies, antibody-drug conjugates, novel imaging techniques, and patient-centered outcomes in advanced urothelial and prostate cancers. The research trends show a consistent focus on biomarker discovery, therapeutic resistance, and the development of personalized treatment strategies.

• Fulbright Scholarship in Medical Ethics (2006)
• ASCO Young Investigator Award (2010)
• Prostate Cancer Foundation Young Investigator Award (2012)
• DoD Physician Research Training Award (2012)
• UCSF Teaching Award (2019)

Dr. Friedlander is a principal or co-investigator on multiple clinical trials and leads a collaborative research program at ZSFG. He has received significant grant support from organizations like the Prostate Cancer Foundation and the Department of Defense. While specific advisees are not listed, his leadership role involves mentoring numerous researchers and clinicians. His team includes experts in medical oncology, genomics, and patient-centered research, fostering interdisciplinary collaboration across UCSF campuses.

He is actively involved in national guideline development, including the NCCN Guidelines for Bladder Cancer, and his work has been widely cited and featured in clinical guidelines and policy discussions.